GlutaredoxinV1, Main, Exploration, bibRecord, 000215

Serum Glutaredoxin Activity as a Marker of Oxidative Stress in Chronic Kidney Disease: A Pilot Study.

Identifieur interne : 000215 ( Main/Exploration ); précédent : 000214; suivant : 000216

Serum Glutaredoxin Activity as a Marker of Oxidative Stress in Chronic Kidney Disease: A Pilot Study.

Auteurs : Anna Levin [Suède] ; Deepika Nair [Suède] ; Abdul Rashid Qureshi [Suède] ; Peter Bárány [Suède] ; Olof Heimburger [Suède] ; Björn Anderstam [Suède] ; Peter Stenvinkel [Suède] ; Annette Bruchfeld [Suède] ; Johanna S. Ungerstedt [Suède]

Source :

Nephron [ 2235-3186 ] ; 2018.

RBID : pubmed:30253414

Descripteurs français

English descriptors

KwdEn :
- Adult (MeSH), Aged (MeSH), Biomarkers (blood), Disease Progression (MeSH), Female (MeSH), Glomerular Filtration Rate (MeSH), Glutaredoxins (blood), Humans (MeSH), Interleukin-6 (blood), Kidney Function Tests (MeSH), Male (MeSH), Middle Aged (MeSH), Oxidative Stress (MeSH), Peritoneal Dialysis (MeSH), Pilot Projects (MeSH), Prospective Studies (MeSH), Renal Insufficiency, Chronic (blood), Renal Insufficiency, Chronic (therapy), Young Adult (MeSH).
MESH :
- chemical , blood : Biomarkers, Glutaredoxins, Interleukin-6.
- blood : Renal Insufficiency, Chronic.
- therapy : Renal Insufficiency, Chronic.
- Adult, Aged, Disease Progression, Female, Glomerular Filtration Rate, Humans, Kidney Function Tests, Male, Middle Aged, Oxidative Stress, Peritoneal Dialysis, Pilot Projects, Prospective Studies, Young Adult.

Abstract

BACKGROUND

Inflammation and oxidative stress play important roles in the pathogenesis and progression of chronic kidney disease (CKD) and in its complications, in particular cardiovascular disease, a major cause of death among patients undergoing dialysis treatment. We recently described that Glutaredoxin1 (Grx), an intracellular antioxidant, catalyzes oxidoreductase reactions also extracellularly, and that serum Grx levels correlate to disease severity in type 2 diabetes.

AIM

In the current study we assess Grx as a potential clinical marker of oxidative stress in CKD.

METHODS

We examined Grx activity in 25 patients with different stages of chronic kidney failure, 19 control subjects, and 36 patients at initiation of dialysis and after 2 years of dialysis.

RESULTS

We found that Grx activity was significantly higher in CKD patients compared to control subjects, indicating an oxidized extracellular environment in CKD. Grx levels correlated to interleukin-6 and pentosidine, but not to age or GFR. In dialysis patients with Grx sampling before dialysis start and after 2 years of dialysis, Grx levels increased more in hemodialysis (HD) patients than in peritoneal dialysis patients, indicating an increased oxidative stress imbalance in HD patients. Patients who experienced a stroke or myocardial infarction at any time had a significantly higher increase in Grx during the 2 years of dialysis, compared to patients without stroke or myocardial infarction, indicating a possible association between high Grx levels and a cardiovascular event.

CONCLUSION

Our pilot study indicates that Grx may be a useful marker for assessing the degree of oxidative stress in CKD, however this needs further investigation in a larger prospective patient cohort.

DOI: 10.1159/000492500
PubMed: 30253414

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000208
to stream Main, to step Curation: 000208

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Serum Glutaredoxin Activity as a Marker of Oxidative Stress in Chronic Kidney Disease: A Pilot Study.</title>
<author><name sortKey="Levin, Anna" sort="Levin, Anna" uniqKey="Levin A" first="Anna" last="Levin">Anna Levin</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Clinical Science, Intervention and Technology, Stockholm, Sweden.</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Department of Clinical Science, Intervention and Technology, Stockholm</wicri:regionArea>
<placeName><settlement type="city">Stockholm</settlement>
<region nuts="2">Svealand</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Nair, Deepika" sort="Nair, Deepika" uniqKey="Nair D" first="Deepika" last="Nair">Deepika Nair</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden.</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Department of Medicine, Huddinge, Karolinska Institutet, Stockholm</wicri:regionArea>
<placeName><settlement type="city">Stockholm</settlement>
<region nuts="2">Svealand</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Qureshi, Abdul Rashid" sort="Qureshi, Abdul Rashid" uniqKey="Qureshi A" first="Abdul Rashid" last="Qureshi">Abdul Rashid Qureshi</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Clinical Science, Intervention and Technology, Stockholm, Sweden.</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Department of Clinical Science, Intervention and Technology, Stockholm</wicri:regionArea>
<placeName><settlement type="city">Stockholm</settlement>
<region nuts="2">Svealand</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Barany, Peter" sort="Barany, Peter" uniqKey="Barany P" first="Peter" last="Bárány">Peter Bárány</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Clinical Science, Intervention and Technology, Stockholm, Sweden.</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Department of Clinical Science, Intervention and Technology, Stockholm</wicri:regionArea>
<placeName><settlement type="city">Stockholm</settlement>
<region nuts="2">Svealand</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Heimburger, Olof" sort="Heimburger, Olof" uniqKey="Heimburger O" first="Olof" last="Heimburger">Olof Heimburger</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Clinical Science, Intervention and Technology, Stockholm, Sweden.</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Department of Clinical Science, Intervention and Technology, Stockholm</wicri:regionArea>
<placeName><settlement type="city">Stockholm</settlement>
<region nuts="2">Svealand</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Anderstam, Bjorn" sort="Anderstam, Bjorn" uniqKey="Anderstam B" first="Björn" last="Anderstam">Björn Anderstam</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Clinical Science, Intervention and Technology, Stockholm, Sweden.</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Department of Clinical Science, Intervention and Technology, Stockholm</wicri:regionArea>
<placeName><settlement type="city">Stockholm</settlement>
<region nuts="2">Svealand</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Stenvinkel, Peter" sort="Stenvinkel, Peter" uniqKey="Stenvinkel P" first="Peter" last="Stenvinkel">Peter Stenvinkel</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Clinical Science, Intervention and Technology, Stockholm, Sweden.</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Department of Clinical Science, Intervention and Technology, Stockholm</wicri:regionArea>
<placeName><settlement type="city">Stockholm</settlement>
<region nuts="2">Svealand</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bruchfeld, Annette" sort="Bruchfeld, Annette" uniqKey="Bruchfeld A" first="Annette" last="Bruchfeld">Annette Bruchfeld</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Clinical Science, Intervention and Technology, Stockholm, Sweden.</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Department of Clinical Science, Intervention and Technology, Stockholm</wicri:regionArea>
<placeName><settlement type="city">Stockholm</settlement>
<region nuts="2">Svealand</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ungerstedt, Johanna S" sort="Ungerstedt, Johanna S" uniqKey="Ungerstedt J" first="Johanna S" last="Ungerstedt">Johanna S. Ungerstedt</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Swedenjohanna.ungerstedt@ki.se.</nlm:affiliation>
<country wicri:rule="url">Suède</country>
<wicri:regionArea>Department of Medicine, Huddinge, Karolinska Institutet, Stockholm</wicri:regionArea>
<placeName><settlement type="city">Stockholm</settlement>
<region nuts="2">Svealand</region>
</placeName>
</affiliation>
<affiliation wicri:level="3"><nlm:affiliation>Hematology Center, Karolinska University Hospital, Stockholm, Swedenjohanna.ungerstedt@ki.se.</nlm:affiliation>
<country wicri:rule="url">Suède</country>
<wicri:regionArea>Hematology Center, Karolinska University Hospital, Stockholm</wicri:regionArea>
<placeName><settlement type="city">Stockholm</settlement>
<region nuts="2">Svealand</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2018">2018</date>
<idno type="RBID">pubmed:30253414</idno>
<idno type="pmid">30253414</idno>
<idno type="doi">10.1159/000492500</idno>
<idno type="wicri:Area/Main/Corpus">000208</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000208</idno>
<idno type="wicri:Area/Main/Curation">000208</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000208</idno>
<idno type="wicri:Area/Main/Exploration">000208</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Serum Glutaredoxin Activity as a Marker of Oxidative Stress in Chronic Kidney Disease: A Pilot Study.</title>
<author><name sortKey="Levin, Anna" sort="Levin, Anna" uniqKey="Levin A" first="Anna" last="Levin">Anna Levin</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Clinical Science, Intervention and Technology, Stockholm, Sweden.</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Department of Clinical Science, Intervention and Technology, Stockholm</wicri:regionArea>
<placeName><settlement type="city">Stockholm</settlement>
<region nuts="2">Svealand</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Nair, Deepika" sort="Nair, Deepika" uniqKey="Nair D" first="Deepika" last="Nair">Deepika Nair</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden.</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Department of Medicine, Huddinge, Karolinska Institutet, Stockholm</wicri:regionArea>
<placeName><settlement type="city">Stockholm</settlement>
<region nuts="2">Svealand</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Qureshi, Abdul Rashid" sort="Qureshi, Abdul Rashid" uniqKey="Qureshi A" first="Abdul Rashid" last="Qureshi">Abdul Rashid Qureshi</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Clinical Science, Intervention and Technology, Stockholm, Sweden.</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Department of Clinical Science, Intervention and Technology, Stockholm</wicri:regionArea>
<placeName><settlement type="city">Stockholm</settlement>
<region nuts="2">Svealand</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Barany, Peter" sort="Barany, Peter" uniqKey="Barany P" first="Peter" last="Bárány">Peter Bárány</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Clinical Science, Intervention and Technology, Stockholm, Sweden.</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Department of Clinical Science, Intervention and Technology, Stockholm</wicri:regionArea>
<placeName><settlement type="city">Stockholm</settlement>
<region nuts="2">Svealand</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Heimburger, Olof" sort="Heimburger, Olof" uniqKey="Heimburger O" first="Olof" last="Heimburger">Olof Heimburger</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Clinical Science, Intervention and Technology, Stockholm, Sweden.</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Department of Clinical Science, Intervention and Technology, Stockholm</wicri:regionArea>
<placeName><settlement type="city">Stockholm</settlement>
<region nuts="2">Svealand</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Anderstam, Bjorn" sort="Anderstam, Bjorn" uniqKey="Anderstam B" first="Björn" last="Anderstam">Björn Anderstam</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Clinical Science, Intervention and Technology, Stockholm, Sweden.</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Department of Clinical Science, Intervention and Technology, Stockholm</wicri:regionArea>
<placeName><settlement type="city">Stockholm</settlement>
<region nuts="2">Svealand</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Stenvinkel, Peter" sort="Stenvinkel, Peter" uniqKey="Stenvinkel P" first="Peter" last="Stenvinkel">Peter Stenvinkel</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Clinical Science, Intervention and Technology, Stockholm, Sweden.</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Department of Clinical Science, Intervention and Technology, Stockholm</wicri:regionArea>
<placeName><settlement type="city">Stockholm</settlement>
<region nuts="2">Svealand</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bruchfeld, Annette" sort="Bruchfeld, Annette" uniqKey="Bruchfeld A" first="Annette" last="Bruchfeld">Annette Bruchfeld</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Clinical Science, Intervention and Technology, Stockholm, Sweden.</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Department of Clinical Science, Intervention and Technology, Stockholm</wicri:regionArea>
<placeName><settlement type="city">Stockholm</settlement>
<region nuts="2">Svealand</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ungerstedt, Johanna S" sort="Ungerstedt, Johanna S" uniqKey="Ungerstedt J" first="Johanna S" last="Ungerstedt">Johanna S. Ungerstedt</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Swedenjohanna.ungerstedt@ki.se.</nlm:affiliation>
<country wicri:rule="url">Suède</country>
<wicri:regionArea>Department of Medicine, Huddinge, Karolinska Institutet, Stockholm</wicri:regionArea>
<placeName><settlement type="city">Stockholm</settlement>
<region nuts="2">Svealand</region>
</placeName>
</affiliation>
<affiliation wicri:level="3"><nlm:affiliation>Hematology Center, Karolinska University Hospital, Stockholm, Swedenjohanna.ungerstedt@ki.se.</nlm:affiliation>
<country wicri:rule="url">Suède</country>
<wicri:regionArea>Hematology Center, Karolinska University Hospital, Stockholm</wicri:regionArea>
<placeName><settlement type="city">Stockholm</settlement>
<region nuts="2">Svealand</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Nephron</title>
<idno type="eISSN">2235-3186</idno>
<imprint><date when="2018" type="published">2018</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term>
<term>Aged (MeSH)</term>
<term>Biomarkers (blood)</term>
<term>Disease Progression (MeSH)</term>
<term>Female (MeSH)</term>
<term>Glomerular Filtration Rate (MeSH)</term>
<term>Glutaredoxins (blood)</term>
<term>Humans (MeSH)</term>
<term>Interleukin-6 (blood)</term>
<term>Kidney Function Tests (MeSH)</term>
<term>Male (MeSH)</term>
<term>Middle Aged (MeSH)</term>
<term>Oxidative Stress (MeSH)</term>
<term>Peritoneal Dialysis (MeSH)</term>
<term>Pilot Projects (MeSH)</term>
<term>Prospective Studies (MeSH)</term>
<term>Renal Insufficiency, Chronic (blood)</term>
<term>Renal Insufficiency, Chronic (therapy)</term>
<term>Young Adult (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte (MeSH)</term>
<term>Adulte d'âge moyen (MeSH)</term>
<term>Dialyse péritonéale (MeSH)</term>
<term>Débit de filtration glomérulaire (MeSH)</term>
<term>Femelle (MeSH)</term>
<term>Glutarédoxines (sang)</term>
<term>Humains (MeSH)</term>
<term>Insuffisance rénale chronique (sang)</term>
<term>Insuffisance rénale chronique (thérapie)</term>
<term>Interleukine-6 (sang)</term>
<term>Jeune adulte (MeSH)</term>
<term>Marqueurs biologiques (sang)</term>
<term>Mâle (MeSH)</term>
<term>Projets pilotes (MeSH)</term>
<term>Stress oxydatif (MeSH)</term>
<term>Sujet âgé (MeSH)</term>
<term>Tests de la fonction rénale (MeSH)</term>
<term>Études prospectives (MeSH)</term>
<term>Évolution de la maladie (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Biomarkers</term>
<term>Glutaredoxins</term>
<term>Interleukin-6</term>
</keywords>
<keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Renal Insufficiency, Chronic</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Glutarédoxines</term>
<term>Insuffisance rénale chronique</term>
<term>Interleukine-6</term>
<term>Marqueurs biologiques</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Renal Insufficiency, Chronic</term>
</keywords>
<keywords scheme="MESH" qualifier="thérapie" xml:lang="fr"><term>Insuffisance rénale chronique</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Disease Progression</term>
<term>Female</term>
<term>Glomerular Filtration Rate</term>
<term>Humans</term>
<term>Kidney Function Tests</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Oxidative Stress</term>
<term>Peritoneal Dialysis</term>
<term>Pilot Projects</term>
<term>Prospective Studies</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Dialyse péritonéale</term>
<term>Débit de filtration glomérulaire</term>
<term>Femelle</term>
<term>Humains</term>
<term>Jeune adulte</term>
<term>Mâle</term>
<term>Projets pilotes</term>
<term>Stress oxydatif</term>
<term>Sujet âgé</term>
<term>Tests de la fonction rénale</term>
<term>Études prospectives</term>
<term>Évolution de la maladie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b>
</p>
<p>Inflammation and oxidative stress play important roles in the pathogenesis and progression of chronic kidney disease (CKD) and in its complications, in particular cardiovascular disease, a major cause of death among patients undergoing dialysis treatment. We recently described that Glutaredoxin1 (Grx), an intracellular antioxidant, catalyzes oxidoreductase reactions also extracellularly, and that serum Grx levels correlate to disease severity in type 2 diabetes.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>AIM</b>
</p>
<p>In the current study we assess Grx as a potential clinical marker of oxidative stress in CKD.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>METHODS</b>
</p>
<p>We examined Grx activity in 25 patients with different stages of chronic kidney failure, 19 control subjects, and 36 patients at initiation of dialysis and after 2 years of dialysis.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>RESULTS</b>
</p>
<p>We found that Grx activity was significantly higher in CKD patients compared to control subjects, indicating an oxidized extracellular environment in CKD. Grx levels correlated to interleukin-6 and pentosidine, but not to age or GFR. In dialysis patients with Grx sampling before dialysis start and after 2 years of dialysis, Grx levels increased more in hemodialysis (HD) patients than in peritoneal dialysis patients, indicating an increased oxidative stress imbalance in HD patients. Patients who experienced a stroke or myocardial infarction at any time had a significantly higher increase in Grx during the 2 years of dialysis, compared to patients without stroke or myocardial infarction, indicating a possible association between high Grx levels and a cardiovascular event.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>CONCLUSION</b>
</p>
<p>Our pilot study indicates that Grx may be a useful marker for assessing the degree of oxidative stress in CKD, however this needs further investigation in a larger prospective patient cohort.</p>
</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30253414</PMID>
<DateCompleted><Year>2019</Year>
<Month>10</Month>
<Day>02</Day>
</DateCompleted>
<DateRevised><Year>2019</Year>
<Month>10</Month>
<Day>02</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2235-3186</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>140</Volume>
<Issue>4</Issue>
<PubDate><Year>2018</Year>
</PubDate>
</JournalIssue>
<Title>Nephron</Title>
<ISOAbbreviation>Nephron</ISOAbbreviation>
</Journal>
<ArticleTitle>Serum Glutaredoxin Activity as a Marker of Oxidative Stress in Chronic Kidney Disease: A Pilot Study.</ArticleTitle>
<Pagination><MedlinePgn>249-256</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1159/000492500</ELocationID>
<Abstract><AbstractText Label="BACKGROUND">Inflammation and oxidative stress play important roles in the pathogenesis and progression of chronic kidney disease (CKD) and in its complications, in particular cardiovascular disease, a major cause of death among patients undergoing dialysis treatment. We recently described that Glutaredoxin1 (Grx), an intracellular antioxidant, catalyzes oxidoreductase reactions also extracellularly, and that serum Grx levels correlate to disease severity in type 2 diabetes.</AbstractText>
<AbstractText Label="AIM">In the current study we assess Grx as a potential clinical marker of oxidative stress in CKD.</AbstractText>
<AbstractText Label="METHODS">We examined Grx activity in 25 patients with different stages of chronic kidney failure, 19 control subjects, and 36 patients at initiation of dialysis and after 2 years of dialysis.</AbstractText>
<AbstractText Label="RESULTS">We found that Grx activity was significantly higher in CKD patients compared to control subjects, indicating an oxidized extracellular environment in CKD. Grx levels correlated to interleukin-6 and pentosidine, but not to age or GFR. In dialysis patients with Grx sampling before dialysis start and after 2 years of dialysis, Grx levels increased more in hemodialysis (HD) patients than in peritoneal dialysis patients, indicating an increased oxidative stress imbalance in HD patients. Patients who experienced a stroke or myocardial infarction at any time had a significantly higher increase in Grx during the 2 years of dialysis, compared to patients without stroke or myocardial infarction, indicating a possible association between high Grx levels and a cardiovascular event.</AbstractText>
<AbstractText Label="CONCLUSION">Our pilot study indicates that Grx may be a useful marker for assessing the degree of oxidative stress in CKD, however this needs further investigation in a larger prospective patient cohort.</AbstractText>
<CopyrightInformation>© 2018 S. Karger AG, Basel.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Levin</LastName>
<ForeName>Anna</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Department of Clinical Science, Intervention and Technology, Stockholm, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Nair</LastName>
<ForeName>Deepika</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Qureshi</LastName>
<ForeName>Abdul Rashid</ForeName>
<Initials>AR</Initials>
<AffiliationInfo><Affiliation>Department of Clinical Science, Intervention and Technology, Stockholm, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bárány</LastName>
<ForeName>Peter</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Department of Clinical Science, Intervention and Technology, Stockholm, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Heimburger</LastName>
<ForeName>Olof</ForeName>
<Initials>O</Initials>
<AffiliationInfo><Affiliation>Department of Clinical Science, Intervention and Technology, Stockholm, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Anderstam</LastName>
<ForeName>Björn</ForeName>
<Initials>B</Initials>
<AffiliationInfo><Affiliation>Department of Clinical Science, Intervention and Technology, Stockholm, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Stenvinkel</LastName>
<ForeName>Peter</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Department of Clinical Science, Intervention and Technology, Stockholm, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bruchfeld</LastName>
<ForeName>Annette</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Department of Clinical Science, Intervention and Technology, Stockholm, Sweden.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ungerstedt</LastName>
<ForeName>Johanna S</ForeName>
<Initials>JS</Initials>
<AffiliationInfo><Affiliation>Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Swedenjohanna.ungerstedt@ki.se.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Hematology Center, Karolinska University Hospital, Stockholm, Swedenjohanna.ungerstedt@ki.se.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2018</Year>
<Month>09</Month>
<Day>25</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Switzerland</Country>
<MedlineTA>Nephron</MedlineTA>
<NlmUniqueID>0331777</NlmUniqueID>
<ISSNLinking>1660-8151</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C516005">GLRX protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D054477">Glutaredoxins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C508600">IL6 protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005919" MajorTopicYN="N">Glomerular Filtration Rate</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D054477" MajorTopicYN="N">Glutaredoxins</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007677" MajorTopicYN="N">Kidney Function Tests</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018384" MajorTopicYN="Y">Oxidative Stress</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010530" MajorTopicYN="N">Peritoneal Dialysis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051436" MajorTopicYN="N">Renal Insufficiency, Chronic</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Diabetes</Keyword>
<Keyword MajorTopicYN="Y">Dialysis</Keyword>
<Keyword MajorTopicYN="Y">Glutaredoxin</Keyword>
<Keyword MajorTopicYN="Y">Interleukin -6</Keyword>
<Keyword MajorTopicYN="Y">Oxidative stress</Keyword>
<Keyword MajorTopicYN="Y">Pentosidine</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year>
<Month>03</Month>
<Day>18</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2018</Year>
<Month>07</Month>
<Day>25</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2018</Year>
<Month>9</Month>
<Day>27</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2019</Year>
<Month>10</Month>
<Day>3</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2018</Year>
<Month>9</Month>
<Day>26</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">30253414</ArticleId>
<ArticleId IdType="pii">000492500</ArticleId>
<ArticleId IdType="doi">10.1159/000492500</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Suède</li>
</country>
<region><li>Svealand</li>
</region>
<settlement><li>Stockholm</li>
</settlement>
</list>
<tree><country name="Suède"><region name="Svealand"><name sortKey="Levin, Anna" sort="Levin, Anna" uniqKey="Levin A" first="Anna" last="Levin">Anna Levin</name>
</region>
<name sortKey="Anderstam, Bjorn" sort="Anderstam, Bjorn" uniqKey="Anderstam B" first="Björn" last="Anderstam">Björn Anderstam</name>
<name sortKey="Barany, Peter" sort="Barany, Peter" uniqKey="Barany P" first="Peter" last="Bárány">Peter Bárány</name>
<name sortKey="Bruchfeld, Annette" sort="Bruchfeld, Annette" uniqKey="Bruchfeld A" first="Annette" last="Bruchfeld">Annette Bruchfeld</name>
<name sortKey="Heimburger, Olof" sort="Heimburger, Olof" uniqKey="Heimburger O" first="Olof" last="Heimburger">Olof Heimburger</name>
<name sortKey="Nair, Deepika" sort="Nair, Deepika" uniqKey="Nair D" first="Deepika" last="Nair">Deepika Nair</name>
<name sortKey="Qureshi, Abdul Rashid" sort="Qureshi, Abdul Rashid" uniqKey="Qureshi A" first="Abdul Rashid" last="Qureshi">Abdul Rashid Qureshi</name>
<name sortKey="Stenvinkel, Peter" sort="Stenvinkel, Peter" uniqKey="Stenvinkel P" first="Peter" last="Stenvinkel">Peter Stenvinkel</name>
<name sortKey="Ungerstedt, Johanna S" sort="Ungerstedt, Johanna S" uniqKey="Ungerstedt J" first="Johanna S" last="Ungerstedt">Johanna S. Ungerstedt</name>
<name sortKey="Ungerstedt, Johanna S" sort="Ungerstedt, Johanna S" uniqKey="Ungerstedt J" first="Johanna S" last="Ungerstedt">Johanna S. Ungerstedt</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Bois/explor/GlutaredoxinV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000215 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000215 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Bois
   |area=    GlutaredoxinV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:30253414
   |texte=   Serum Glutaredoxin Activity as a Marker of Oxidative Stress in Chronic Kidney Disease: A Pilot Study.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:30253414" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a GlutaredoxinV1

This area was generated with Dilib version V0.6.37.
Data generation: Wed Nov 18 15:13:42 2020. Site generation: Wed Nov 18 15:16:12 2020

	Serveur d'exploration sur la glutarédoxine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur la glutarédoxine

Serum Glutaredoxin Activity as a Marker of Oxidative Stress in Chronic Kidney Disease: A Pilot Study.

Serum Glutaredoxin Activity as a Marker of Oxidative Stress in Chronic Kidney Disease: A Pilot Study.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki